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Dr Kenneth A. Kesler (Indianapolis, Ind). For many years, we
have measured indicators, such as operative mortality, levels of
morbidity, and cure rates, to determine the success of treatment
for locally advanced esophageal cancer, and we have made reason-
able progress with respect to all of these particular variables over
time. The operative risks for these operations have become accept-
able. Induction therapy with cisplatin-based chemotherapy and
concurrent radiation therapy has, for the most part, become ac-
cepted as the treatment of choice for patients with adequate perfor-
mance status. As the authors of this study point out, however,
overall survival improvements with induction therapy have been
unfortunately modest, and meaningful survival benefits are proba-
bly limited to the subset of patients who demonstrate a significant or
complete pathologic response. Until we have some mechanism to
identify the subset of patients who will significantly benefit from
platin-based induction therapy or, better yet, we have more effec-
tive chemotherapy agents, many patients with locally advanced
esophageal cancer will not only not derive survival benefit from in-
duction therapy but, as this prospective study demonstrates, will ex-
perience morbidity, including a temporary loss of QOL, which is
significant in patients with limited median survival.
We therefore acknowledge the efforts of Dr Darling and her col-
leagues inToronto, who have taken the next step tomeasureHRQOL
as an important outcome variable. This study will not only serve as
a point of reference with respect to QOL outcomes for this particular
induction treatment strategy but hopefully as a starting point at which
QOL instruments are routinely included in future prospective clinical
trials for locally advanced esophageal cancer.
I have 3 questions. In this study you used the FACT-E question-
naire to quantitate HRQOL, which is an instrument you have
validated in a previous study. Do you believe, however, future re-
finements to this instrument might be helpful, such as refinements
to better capture potentially serious side effects after esophagec-
tomy, such as dumping, reflux, or delayed gastric emptying, which
might not be identified with this instrument or any other currently
used instruments for that matter?
Dr Darling. Thank you, Dr Kesler. I think that is a very good
point.
The item generation for the esophageal cancer subscale was de-
veloped from patients with recently diagnosed esophageal cancer
rather than from patients after esophagectomy. I agree that it prob-
ably does not completely address postesophagectomy problems.
We have not initiated any refinements, but I think it warrants further
study. I think that we are seeing a little bit of those problems whenThe Journal of Thoracic and Cwe look at the eating index after surgical intervention. As we who
treat these patients all know, their eating can be significantly af-
fected by dumping syndrome or other problems after esophagec-
tomy, and I think that is being reflected in the eating index.
However, it is probably worthwhile for us to take another look at
it and to address some of those postesophagectomy issues.
Dr Kesler. Although the patients in this study returned to base-
line HRQOL scores relatively quickly after both induction therapy
and esophagectomy, the baseline score was measured after disease
diagnosis. At diagnosis, most of these patients were symptomatic
with dysphagia and weight loss, not to mention having experienced
the psychologic consequences of being told they have a cancer that
is not frequently cured. Do you think it is possible to somehow
establish a baseline HRQOL score reflecting both physical and
mental status before illness that would help differentiate the effect
of the disease from the effect of the treatment and additionally pro-
vide a more accurate reference point to compare against QOL mea-
surements over time?
Dr Darling. That is a very good question also. I think it would
be difficult because most of these patients are referred already
knowing the diagnosis. The fact that the emotional well-being
score remains stable throughout the treatment protocol and there-
after speaks to the resilience of some of these patients with respect
to that component of QOL. Therefore I do not think that it would
be particularly different if we somehow picked them up before
they actually had the diagnosis. We know that if we compare
QOL with the Short Form–36 (SF-36), which is designed for
normal persons, and measure QOL in patients with cancer, more
specifically esophageal cancer, that their QOL is significantly
less than we would see in healthy subjects, but I am not sure
how to capture them before they have actually been given the
diagnosis.
Dr Kesler. Lastly, the finding that patients who died within 1
year of diagnosis, presumably of recurrent disease, demonstrated
a significant decrease in QOL compared with 1-year survivors
seems fairly intuitive and would be expected. Did the decrease in
QOL observed in these patients happen to precede any clinical or
radiographic evidence of cancer? As a corollary, do you think
this represents a potential marker that can be clinically useful to
detect recurrence?
Dr Darling. The decrease in QOL scores did precede the radio-
logic diagnosis of recurrence. These patients were all on study, and
therefore they were receiving routine computed tomographic scans
looking for recurrence. But the QOL scores decreased and were not
recovering before any imaging changes, and therefore we were al-
ready worried. I am sure we all have had those patients in our prac-
tice. They just do not get better after esophagectomy, and you are
trying to figure out why. I think the FACT-E might be clinically
useful in the future as a marker for recurrent disease. I have cer-
tainly already adopted it. When I have that patient who is just not
getting better, I start looking harder. Just to be clear, these patients
were not aware that they had recurrence, and we were not aware
that they had recurrence at the time those questionnaires were com-
pleted. I do think it will be a useful marker.
Dr Kesler. Thank you. Congratulations.
Dr Darling: Thank you very much.
DrScott J. Swanson (NewYork, NY). I would like to follow up on
that last point because it is very intriguing.Doyou think if you hadnotardiovascular Surgery c Volume 137, Number 1 41
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Soperated on those patients that theywould have had a steady decrease
in their QOL scores? Is there something about the operation or the in-
tensity of the treatment unmasking their ability to handle cancer, and
is it actually speeding up dissemination in some way? What do you
think is the actual mechanism that is going on there?
Dr Darling. We know historically that patients who were not
cured by means of esophagectomy had a median survival of 9 to
12 months. I think we are actually just seeing that same time course
in these patients for whom our treatment protocol did not improve
their survival. I do not think it is the effect of the operation or the
induction that causes that decrease in QOL score. I think we would
have seen it anyway.
Dr Douglas E. Wood (Seattle, Wash). Gail, I am interested in
whether you think that the scale that you used, a cancer-specific
QOL scale, might be indeed what we want to capture, or might
we actually be interested in a more general QOL scale, such as
SF-36, for these patients? This is very important work. There is
clearly a bias in our medical colleagues that patients have a poor
QOL relating to treatment, including esophagectomy, for esopha-
geal cancer. I do not know enough about the scale that you used
to know the differences and the nuances and whether our argument
might be stronger if we chose a generalized scale.42 The Journal of Thoracic and Cardiovascular SurgDr Darling. Well, I think they are complementary. If you want
to compare a healthy population with a disease-specific population,
a cancer population, you can use the SF-36. Therefore it depends on
your question. We are particularly interested in comparing cancer
therapies. We are trying to cure more esophageal cancer but at
a price of the toxicity. Therefore our goal in using a cancer-specific
instrument was to use it in the future for comparing different treat-
ment protocols. The SF-36would be useful in addressing a different
question, such as whether patients with esophagectomy get back to
a ‘‘normal’’ QOL score.
Dr Alec Patterson (St Louis, Mo). Gail, I enjoyed the article.
I noticed that 20% of the patients did not complete the program.
Dr Darling. Yes.
Dr Patterson. Were they all from Toronto? I mean, did you
have any handle on the quality of the induction therapy?
Dr Darling. They were essentially all from Toronto. Some of
the chemotherapy was delivered elsewhere, but in fact, all the pa-
tients who did not complete it were actually at our center. Some
were patients who were not overly enthusiastic about chemother-
apy and were not tolerant of any side effects. They did not stop
for specific toxicity reasons. It was not a case of an outside oncol-
ogist not supporting the trial.ery c January 2009
